DC’s Clayface is scheduled for an October 23, 2026, theatrical release, as the studio pivots into R-rated body horror. Described as a visceral psychological thriller, the film represents a departure from traditional superhero tropes.
Directed by James Watkins, the film stars Tom Rhys Harries as Matt Hagen, a struggling actor whose life is derailed by a disfiguring accident. In a desperate bid to restore his appearance, Hagen undergoes a treatment that transforms his physical form into a malleable, living clay. This iteration of the character focuses on the tragic and grotesque nature of his transformation rather than his history as a traditional Batman antagonist, with reports confirming that the story is set in Gotham City.
A Leaner, Darker Breed of Superhero Cinema
Produced on a relatively modest budget of approximately $40 million, Clayface represents a significant shift from the $200 million spectacles often associated with the genre. This focused scope appears to have allowed for a more intense creative direction. Screenwriter Mike Flanagan, who co-wrote the script with Hossein Amini, has infused the story with the atmospheric dread found in his previous horror projects.
The film’s practical and visual effects have drawn comparisons to David Cronenberg’s 1986 classic The Fly and Sam Raimi’s Darkman, as well as the recent body-horror entry The Substance. These comparisons underscore a narrative that prioritizes the “freakishly awesome” and “unsettling” aspects of Hagen’s condition over typical action sequences. Brandon Davis of ComicBook.com notably praised Watkins’ “unsettling take on Gotham,” signaling that the setting feels as much a character as the lead actor himself.
Performance and Tone
The film’s R-rated approach allows for a graphic exploration of Matt Hagen’s physical decay and eventual metamorphosis. This psychological depth is a cornerstone of the project, focusing on the balance between the vulnerability of a disfigured man and the rising horror of a creature losing its humanity.
According to official production details, the film functions as a standalone entry. By focusing on a character-driven horror narrative rather than a shared-universe crossover, the project serves as a proof of concept for the tonal diversity promised for future DC Studios projects. This “body-horror bet” indicates a willingness to explore niche genres using established comic book intellectual property, catering to audiences looking for a more mature, genre-specific experience within a superhero framework.
The film’s scheduled wide release on October 23 positions it as a centerpiece for the 2026 Halloween season.
